Notice of Results

Cambridge Nutritional Sciences PLC
10 July 2024
 

CAMBRIDGE NUTRITIONAL SCIENCES PLC

("CNS", the "Company", or the "Group")

 

Notice of Results

&

Investor Presentation via Investor Meet Company

 

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, will announce the Group's Final Results for the year ended 31 March 2024 on Thursday 25 July 2024.

 

Investor Presentation

On the same day at 16:30 BST, Jag Grewal, CEO, and James Cooper, COO, will provide a live presentation relating to the results via Investor Meet Company ("IMC").

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the IMC dashboard up until 24 July 2024, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to IMC for free and add to meet Cambridge Nutritional Sciences PLC via:

https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor

 

Investors who already follow Cambridge Nutritional Sciences PLC on the IMC platform will automatically be invited.

 

 

 

Cambridge Nutritional Sciences Plc         

www.cnsplc.com

Jag Grewal, Chief Executive Officer

investors@cnsplc.com

 

 

Cavendish Capital Markets Limited   

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)

 

Nigel Birks / Harriet Ward (ECM)

 

 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences Plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings